Cargando…

DIPG in Children – What Can We Learn from the Past?

Brainstem tumors represent 10–15% of pediatric central nervous system tumors and diffuse intrinsic pontine glioma (DIPG) is the most common brainstem tumor of childhood. DIPG is almost uniformly fatal and is the leading cause of brain tumor-related death in children. To date, radiation therapy (RT)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vanan, Magimairajan Issai, Eisenstat, David D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4617108/ https://www.ncbi.nlm.nih.gov/pubmed/26557503 http://dx.doi.org/10.3389/fonc.2015.00237

Ejemplares similares

LGG-23. EXCELLENT CLINICAL / RADIOLOGICAL RESPONSE TO BRAF INHIBITION IN A YOUNG CHILD WITH IN-OPERABLE SUPRA-SELLAR PILOCYTIC ASTROCYTOMA
por: Chapman, Stacy, et al.
Publicado: (2020)

SONIC HEDGEHOG (SHH) PROMOTES BLOOD-BRAIN BARRIER (BBB) INTEGRITY IN DIFFUSE MIDLINE GLIOMA OF THE PONS
por: Line, Stacey, et al.
Publicado: (2023)

DIPG-43. CAN WE REPROGRAM DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)? EXPLORING THE ROLE OF DISTALLESS/DLX HOMEOBOX GENE REGULATION OF OLIGODENDROGLIAL PROGENITOR CELLS (OPC) IN THE DEVELOPING VERTEBRATE NERVOUS SYSTEM
por: Nevin, Mikaela, et al.
Publicado: (2020)

Management of Inoperable Supra-Sellar Low-Grade Glioma With BRAF Mutation in Young Children
por: Howden, Kaitlyn, et al.
Publicado: (2021)

COVID‐19 and tourism: What can we learn from the past?
por: Aronica, Martina, et al.
Publicado: (2021)

Renal Cell Cancer: What Can We Learn from Pre-Operative Studies?
por: Fisher, Rosalie, et al.
Publicado: (2011)

Sustained and durable response with Alisertib monotherapy in the treatment of relapsed Atypical Teratoid Rhabdoid Tumor (ATRT)
por: Howden, Kaitlyn, et al.
Publicado: (2022)

Polyorchidism and testicular malignancy, what can we learn: A case report
por: Nurfajri, Derri Hafa, et al.
Publicado: (2021)

Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature
por: Arbour, Gabrielle, et al.
Publicado: (2022)

Future Clinical Trials in DIPG: Bringing Epigenetics to the Clinic
por: Morales La Madrid, Andres, et al.
Publicado: (2015)

What can we learn from more than 1,000 Brazilian patients at risk of hereditary cancer?
por: Leite, Ana Carolina Rathsam, et al.
Publicado: (2022)

Perspectives of pediatric oncologists and palliative care physicians on the therapeutic use of cannabis in children with cancer
por: Oberoi, Sapna, et al.
Publicado: (2021)

Spermidine/Spermine N1-Acetyltransferase 1 (SAT1)—A Potential Gene Target for Selective Sensitization of Glioblastoma Cells Using an Ionizable Lipid Nanoparticle to Deliver siRNA
por: Yathindranath, Vinith, et al.
Publicado: (2022)

DIPG-74. RE-IRRADIATION OF DIPG: DATA FROM THE INTERNATIONAL DIPG REGISTRY
por: Lafay-Cousin, Lucie, et al.
Publicado: (2020)

Comment on “Perineural Invasion In Pancreatic Ductal Adenocarcinoma—What Can We Learn From The Past?’’
por: Shen, Xiaofei
Publicado: (2021)

Paving the Road for Modern Particle Therapy – What Can We Learn from the Experience Gained with Fast Neutron Therapy in Munich?
por: Specht, Hanno M., et al.
Publicado: (2015)

Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?
por: Steenbruggen, Tessa G, et al.
Publicado: (2015)

Lymphopenia in Esophageal Cancer: What Have We Learned?
por: Wang, Jia-Lin, et al.
Publicado: (2021)

What Can We Learn from Charmless Rare B Decays: the Past/Next 3 Years
por: Hou, G W S
Publicado: (2000)

Past, present and future of Focused Ultrasound as an adjunct or complement to DIPG/DMG therapy: A consensus of the 2021 FUSF DIPG meeting
por: Parekh, Kavya, et al.
Publicado: (2023)

What we have learned from the past and how we should look forward
por: Wellmer, Friedrich-W.
Publicado: (2022)

DIPG-21. LINKING DETERMINATION OF CELL FATE IN THE DEVELOPING CENTRAL NERVOUS SYSTEM TO DIFFUSE MIDLINE GLIOMA
por: Furst, Liam, et al.
Publicado: (2023)

Translating palbociclib to the clinic for DIPG - What is truly achievable?
por: Franshaw, Laura, et al.
Publicado: (2019)

Brain Tumor Immunotherapy: What have We Learned so Far?
por: Van Gool, Stefaan Willy
Publicado: (2015)

Modeling WWOX Loss of Function in vivo: What Have We Learned?
por: Tanna, Mayur, et al.
Publicado: (2018)

Aging: What We Can Learn From Elephants
por: Chusyd, Daniella E., et al.
Publicado: (2021)

DIPG-48. DIPG THROUGH THE LOOKING GLASS
por: Senga, Sasi S
Publicado: (2023)

What have we learned in interventional pulmonology in the past decade?
por: ÖZGÜL, Mehmet Akif, et al.
Publicado: (2019)

Editorial: Mechanisms and Therapy for Cancer Metastasis to the Central Nervous System
por: Zhao, Haotian, et al.
Publicado: (2019)

Editorial: Prostate Cancer: What We Know and What We Would Like to Know
por: Taverna, Gianluigi, et al.
Publicado: (2015)

MRD Tailored Therapy in AML: What We Have Learned So Far
por: Ngai, Lok Lam, et al.
Publicado: (2021)

Emergency Responder Health: What Have We Learned from Past Disasters?
por: Weinhold, Bob
Publicado: (2010)

What can we learn from drug marketing efficiency?
por: Kao, David P
Publicado: (2008)

Data Analysis: What Can Be Learned From the Past 50 Years
por: Huber, Peter J
Publicado: (2011)

Canadian Pediatric Neuro-Oncology Standards of Practice
por: Bennett, Julie, et al.
Publicado: (2020)

What Can We Learn from Medical Whistleblowers?
por: Lenzer, Jeanne
Publicado: (2005)

What can we learn from Plausible Values?
por: Marsman, Maarten, et al.
Publicado: (2016)

What can we learn from honey bees?
por: Schwartzman, Julia A
Publicado: (2021)

DIPG-16. Evaluation of myeloid component of DIPG microenvironment
por: Mishra, Deepak, et al.
Publicado: (2022)

DIPG-03. Therapeutic targeting of purine biosynthesis in DIPG
por: Mersich, Ian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hr2ba8fijfr998i2kutbo5et6c